NCT05376878
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 4
Drug Category: Other, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease 
Additional Notes: Patients must have planned therapy with Enhertu/fam-trastuzumab deruxtecan
Exclusions: Patients that do not have at least 1 lesion greater than 1.5 cm evident on MRI; Patients requiring immediate local intervention for brain metastases
https://ClinicalTrials.gov/show/NCT05376878